- ICH GCP
- US Clinical Trials Registry
- Klinisk forsøg NCT00155922
The Gene Expression Patterns in the Peripheral White Blood Cells of Type 2 Diabetic Patients
The Gene Expression Patterns in the Peripheral White Blood Cells of Type 2 Diabetic Patients, Special Relevance to Atherosclerosis
Studieoversigt
Status
Betingelser
Detaljeret beskrivelse
Cardiovascular events are the leading cause of death in developed countries worldwide, including Taiwan. Type 2 diabetes mellitus (T2DM), previously considered merely as one of the risk factors, has been recently unanimously accepted to be coronary artery disease-equivalent. How T2DM may lead to accelerated atherosclerosis remains obscure.
Hyperglycemia with or without hyperinsulinemia may lead to higher oxidative stress and generalized inflammation. The oxidative stress and inflammation may play a significant role in the pathogenesis in diabetic complications, including micro- and macro-vascular complications. Macrophages together with T-lymphocytes are the earliest cell-types found in fatty-streaks, the earliest atherosclerotic lesions. Macrophages are also well known cellular mediators of oxidative stress and inflammation. Therefore, it is plausible to hypothesize that macrophages play a crucial role in the pathogenesis of atherosclerosis in patients with T2DM. In addition, the other cell types of the peripheral white blood cells (WBC), such as neutrophils, have been shown to be intimately related to acute coronary syndrome. Therefore, the study on the biology of peripheral WBCs may tell us something about the pathophysiology of diabetic macro-vascular complications.
Methods:
- Normal control: fasting plasma glucose (FPG) less than 126 mg/dl.
T2DM: FPG >=126 mg/dl.
- Group 1 (good glycemic control): hemoglobin A1c (HbA1c) <= 7% in the past 6 months
- Group 2 (poor glycemic control): HbA1c >= 8% in the past 6 months
- Blood sample will be collected at baseline and after aggressive control.
Undersøgelsestype
Tilmelding
Kontakter og lokationer
Studiesteder
-
-
-
Taipei, Taiwan, 10012
- Rekruttering
- National Taiwan University Hospital
-
Kontakt:
- Wei-Shiung Yang, MD, PhD
- Telefonnummer: 7258 886-2-23123456
- E-mail: wsyang@ha.mc.ntu.edu.tw
-
-
Deltagelseskriterier
Berettigelseskriterier
Aldre berettiget til at studere
Tager imod sunde frivillige
Køn, der er berettiget til at studere
Beskrivelse
Inclusion Criteria:
- Normal control: fasting plasma glucose (FPG) less than 126 mg/dl.
T2DM: FPG >=126 mg/dl.
- Group 1 (good glycemic control): HbA1c<=7% in the past 6 months
- Group 2 (poor glycemic control): HbA1c>=8% in the past 6 months
Exclusion Criteria:
- Acute systemic diseases
Studieplan
Hvordan er undersøgelsen tilrettelagt?
Design detaljer
Samarbejdspartnere og efterforskere
Efterforskere
- Ledende efterforsker: Wei-Shiung Yang, MD, PhD, National Taiwan University Hospital
Datoer for undersøgelser
Studer store datoer
Studiestart
Datoer for studieregistrering
Først indsendt
Først indsendt, der opfyldte QC-kriterier
Først opslået (Skøn)
Opdateringer af undersøgelsesjournaler
Sidste opdatering sendt (Skøn)
Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier
Sidst verificeret
Mere information
Begreber relateret til denne undersøgelse
Yderligere relevante MeSH-vilkår
Andre undersøgelses-id-numre
- 9261700953
Disse oplysninger blev hentet direkte fra webstedet clinicaltrials.gov uden ændringer. Hvis du har nogen anmodninger om at ændre, fjerne eller opdatere dine undersøgelsesoplysninger, bedes du kontakte register@clinicaltrials.gov. Så snart en ændring er implementeret på clinicaltrials.gov, vil denne også blive opdateret automatisk på vores hjemmeside .
Kliniske forsøg med Diabetes mellitus, type 2
-
US Department of Veterans AffairsAmerican Diabetes AssociationAfsluttetType 2 diabetes mellitusForenede Stater
-
Dexa Medica GroupAfsluttetType-2 diabetes mellitusIndonesien
-
University Hospital Inselspital, BerneAfsluttetType 2 diabetes mellitusSchweiz
-
India Diabetes Research Foundation & Dr. A. Ramachandran...Afsluttet
-
AstraZenecaRekruttering
-
Daewoong Pharmaceutical Co. LTD.Ikke rekrutterer endnuT2DM (Type 2 Diabetes Mellitus)
-
Zhongda HospitalRekrutteringType 2 diabetes mellitus (T2DM)Kina
-
Newsoara Biopharma Co., Ltd.RekrutteringT2DM (Type 2 Diabetes Mellitus)Kina
-
Shanghai Golden Leaf MedTec Co. LtdAktiv, ikke rekrutterendeType 2 diabetes mellitus (T2DM)Kina
-
SanofiAfsluttet